Argenx ARGX.BR
Argenx is a biopharmaceutical company that develops and commercializes innovative therapies for autoimmune diseases, with its lead drug Vyvgart as the main source of revenue. Argenx shows solid fundamentals with 59.3% revenue growth and 23.64% ROE, but its demanding valuation (P/E 36.52) and long-term rate pressure limit the appeal.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Argenx is a biopharmaceutical company that develops and commercializes innovative therapies for autoimmune diseases, with its lead drug Vyvgart as the main source of revenue. Argenx shows solid fundamentals with 59.3% revenue growth and 23.64% ROE, but its demanding valuation (P/E 36.52) and long-term rate pressure limit the appeal.
Score by category
| Category | Score |
|---|---|
| Financial health | 9.0 |
| Quality / Moat | 7.7 |
| Valuation | 3.0 |
| Growth | 10.0 |
| Dividend | 1.5 |
| Momentum | 6.5 |
| Risk & Context | 9.1 |
OVERALL SCORE: 6.5/10
Context and risks
High-growth biotech (P/E 36.5) with long-duration cash flows; the rise in 10-year yields to 5.17% pressures its valuation. However, its net cash position eliminates refinancing risk.
News considered in the analysis
- Here's Exactly Why Wall Street Thinks Argenx Stock Could Soar 23% Over the Next 12 Months — Opinión de analistas con objetivo de precio alcista; refleja expectativas de crecimiento ya conocidas, no información nueva material.
- European Equities Traded in the US as American Depositary Receipts Edge Lower in Thursday Trading — Movimiento de mercado sin información específica sobre la empresa.
- argenx (ENXTBR:ARGX) Shares Moved, So What Is Drawing Attention Now? — Artículo genérico sobre movimiento de la acción sin información nueva.
- argenx (ENXTBR:ARGX) Stock Could Be Pricey Despite Strong Earnings Expectations — Advertencia sobre valoración elevada (PER 36.5) que ya está reflejada en la nota cuantitativa de valoración.
- Stock Market Today: Small Caps, Gold Miners Spanked Amid Sell-Off; Meta Makes A Bullish Move — Resumen de mercado general sin relevancia específica para Argenx.
Verdict: Hold; strong growth justifies part of the multiple, but valuation already discounts high expectations.
Main risk: Dependence on Vyvgart as the main revenue source; any regulatory or competitive setback in its key indication would have a material impact.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →